This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- AZD-0424
- DrugBank Accession Number
- DB13088
- Background
AZD0424 has been used in trials studying the treatment of Advanced Solid Tumours.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for AZD-0424 (DB13088)
- Weight
- Average: 528.99
Monoisotopic: 528.1887958 - Chemical Formula
- C25H29ClN6O5
- Synonyms
- Not Available
- External IDs
- AZD0424
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazanaphthalenes
- Sub Class
- Benzodiazines
- Direct Parent
- Quinazolinamines
- Alternative Parents
- Alkyl aryl ethers / Aminopyridines and derivatives / Aminopyrimidines and derivatives / N-alkylpiperazines / Aryl chlorides / Benzenoids / Imidolactams / Acetamides / Tertiary carboxylic acid amides / Heteroaromatic compounds show 10 more
- Substituents
- 1,4-diazinane / Acetal / Acetamide / Alkyl aryl ether / Amine / Amino acid or derivatives / Aminopyridine / Aminopyrimidine / Aromatic heteropolycyclic compound / Aryl chloride show 27 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 642PS51324
- CAS number
- 692054-06-1
- InChI Key
- MVWATCATLSSVBH-UHFFFAOYSA-N
- InChI
- InChI=1S/C25H29ClN6O5/c1-15(2)37-20-11-17(34-9-8-31-4-6-32(7-5-31)16(3)33)10-19-21(20)24(29-13-28-19)30-22-18(26)12-27-25-23(22)35-14-36-25/h10-13,15H,4-9,14H2,1-3H3,(H,27,28,29,30)
- IUPAC Name
- 1-[4-(2-{[4-({6-chloro-2H-[1,3]dioxolo[4,5-b]pyridin-7-yl}amino)-5-(propan-2-yloxy)quinazolin-7-yl]oxy}ethyl)piperazin-1-yl]ethan-1-one
- SMILES
- CC(C)OC1=C2C(NC3=C(Cl)C=NC4=C3OCO4)=NC=NC2=CC(OCCN2CCN(CC2)C(C)=O)=C1
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 1 Terminated Treatment Advanced Solid Tumors 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.128 mg/mL ALOGPS logP 3.33 ALOGPS logP 2.61 Chemaxon logS -3.6 ALOGPS pKa (Strongest Acidic) 11.82 Chemaxon pKa (Strongest Basic) 6.61 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 10 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 111.17 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 136.76 m3·mol-1 Chemaxon Polarizability 54.73 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 212.41634 predictedDeepCCS 1.0 (2019) [M+H]+ 214.8119 predictedDeepCCS 1.0 (2019) [M+Na]+ 220.72443 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 02:53 / Updated at June 12, 2020 16:53